Nicholas Berry

Publications by Year

Research Areas

COVID-19 Clinical Research Studies, Long-Term Effects of COVID-19, Glioma Diagnosis and Treatment, Statistical Methods in Clinical Trials, COVID-19 and Mental Health

Most-Cited Works

• → Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial(2022)395 cited
• → Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial(2021)303 cited
• → Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study(2020)144 cited
• → Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial(2021)77 cited
• → Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients – An Observational Study(2020)69 cited
• → The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials(2022)68 cited
• → Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial(2022)51 cited
• → Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk(2021)28 cited
• → Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial(2021)27 cited
• → Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes(2024)22 cited